E levation in cytosolic Ca 2+ is fundamental to most platelet responses to physiological agonists, including pseudopod formation, integrin α α IIb β 3 activation, secretion, procoagulant activity, and formation of platelet aggregates. 1, 2 Hence, elevated Ca 2+ is a central signaling event in regulating the formation of a multiplatelet thrombus after arterial damage. Surprisingly, attempts to pharmacologically attack platelet Ca 2+ signaling to suppress thrombus formation and, hence, arterial thrombosis have so far been unsuccessful. This is attributable to a lack of knowledge of the molecular mechanism implicated in platelet Ca 2+ signaling and to the absence of suitable Ca 2+ signal inhibitors.
Most platelet agonists raise cytosolic Ca 2+ via inositol 1,4,5-trisphosphate (InsP 3 )-mediated mobilization of Ca 2+ from internal stores in the endoplasmic reticulum, which is dramatically enhanced by Ca 2+ influx from the extracellular medium. [1] [2] [3] Recent work has shown that, in both human and mouse platelets, the Ca 2+ channel Orai1 (also indicated as CRACM1) is responsible for the majority of Ca 2+ entry into activated platelets through the pathway of store-operated Ca 2+ entry (SOCE). [4] [5] [6] The permeability of the Orai1 channel appears to be strictly regulated by the interaction with the Ca 2+ -sensing endoplasmic protein, stromal-interacting molecule 1 (STIM1). 7 Platelets also express other channels implicated in Ca 2+ influx, particularly isoforms of the transient receptor potential channels, transient receptor potential channel 1 and transient receptor potential channel 6, of which only the latter plays a modest role in platelet activation via the pathway of receptor-operated Ca 2+ entry. 8, 9 In other (nonexcitable) cell types, however, these non-Orai Ca 2+ channels can have a more important role.
Recent data using mice deficient in Orai1 or STIM1 have shown that both proteins in platelets play key roles in arterial thrombus formation, as determined in various in vivo thrombosis models. 4, 5 In addition, deficiency in platelet Orai1 or STIM1 appeared to suppress experimental induction of ischemic brain infarction but did not result in a bleeding phenotype. In agreement with this, deficiency in platelet Orai1 July 2012 or STIM1 reduced the buildup of platelet thrombi during high-shear blood flow over a collagen surface. 5, 6, 10 These studies indicated that the Ca 2+ entry process via Orai1 and STIM1 enhanced the formation of platelet aggregates, but was essential for platelet procoagulant activity. 6, 10 Platelet procoagulant activity is induced by strong Ca 2+mobilizing agonists such as collagen, activating the glycoprotein VI (GPVI) receptor, in combination with thrombin, activating the protease-activated receptors (PAR). This response requires a sustained rise in intracellular Ca 2+ , surpassing a threshold level of ≈400 nmol/L. 1, 11 This causes surface exposure of the negatively charged phospholipid, phosphatidylserine (PS), which serves as a binding site for coagulation factors. [12] [13] [14] By providing a key link between platelet and coagulation activation, the platelet procoagulant response was found to regulate arterial thrombus formation in vivo in various experimental mouse models. 15, 16 Considering the relevant role of Orai1 in arterial thrombosis, we hypothesized that pharmacological blockage of the Orai1 channels may provide a novel way of antithrombotic therapy by suppressing platelet aggregate formation and particularly platelet procoagulant activity. In this article, we first screened established and novel pharmacological inhibitors of SOCE for their suppressive effects on platelet Ca 2+ responses and thrombus formation. Using Orai1-deficient platelets, we verified this channel as the target of the most potent inhibitors. We furthermore determined the efficacy of inhibitors to suppress arterial thrombus formation in an established model of ischemic brain infarction.
Methods
For extended information, see the online-only Data Supplement.
Mice
Experiments with mice were approved by the local animal care and use committees. Wild-type C57BL/6, bone marrow chimeras of C57BL/6 mice with Orai1 +/+ or Orai1 −/− platelets have been described before. 10 The latter 2 compounds were selected by their ability to suppress I CRAC in Jurkat or basophilic leukemia cells (see patents). Synta66 and GSK-7975A were >99% pure, as determined by proton nuclear magnetic resonance spectroscopy, liquid chromatography-mass spectrometry, and high-performance liquid chromatography.
Ca 2+ Entry Inhibitors

Platelet Responses in Suspension
Details on platelet responses in suspension are given in the onlineonly Data Supplement.
Thrombus Formation and Platelet Ca 2+ Responses Under Flow
Glass coverslips were coated with 10 μL of 50 μg/mL Horm collagen (1 cm 2 ) for 1 hour in a humid box, and subsequently blocked with 1% BSA in HEPES buffer, pH 7.45. Collagen-coated coverslips were perfused with whole blood that was anticoagulated with phenylanalylprolyl-arginine chroromethyl ketone/fragmin (human) 17 or phenylanalyl-prolyl-arginine chroromethyl ketone/heparin (mouse). 10, 18 Platelets in thrombi were postlabeled with fluorescein isothiocyanate-annexin A5. To measure single-cell Ca 2+ responses under flow, platelets were loaded with fluo-4 acetoxymethyl ester and re-added to autologous blood at an amount of 10% fluo-4-loaded platelets. 19 Inhibitor or vehicle was added 10 minutes before perfusion.
In Vivo Thrombosis
Wild-type or chimeric Orai1 −/− mice were injected with vehicle solution or 2APB (3 mg/kg) as indicated. In blood samples isolated 60 minutes after injection, collagen-induced thrombus formation was measured, as described above. To induce focal cerebral ischemia in mice, the middle cerebral artery (MCA) was transiently occluded for 60 minutes using an intraluminal filament as described elsewhere (transient MCA occlusion model). 20 Immediately after reperfusion of the MCA territory, vehicle solution or 2APB (3 mg/kg) was injected postoperatively. Animals were euthanized on day 1 after transient MCA occlusion, and brain sections were stained with 2% 2,3,5-triphenyltetrazolium chloride to quantify the ischemic brain volume (corrected for edema). 20
Results
Pharmacological Inhibition of Platelet Ca 2+ and Procoagulant Responses
Several compounds known to affect agonist-evoked influx of extracellular Ca 2+ were screened for their potency to block SOCE and exposure of procoagulant PS in washed human platelets. The platelets were stimulated with a combination of strong agonists, convulxin (activating GPVI) and thrombin (activating protease-activated receptors), that is, a condition known to maximally trigger Ca 2+ signaling. 1, 21 Platelet stimulation in the presence of low EGTA (baseline Ca 2+ ≈15 nmol/L) resulted in full mobilization of Ca 2+ from intracellular stores, which was detected as a transient Ca 2+ rise peaking at 400 nmol/L ( Figure 1A ). Subsequent addition of a surplus of CaCl 2 induced massive Ca 2+ influx attributable to SOCE, resulting in Ca 2+ peak levels up to 1300 nmol/L. Candidate compounds tested included the known SOCE inhibitor, bimethoxyphenyl imidazole, SKF96365 22 ; the less well-studied lipophilic biaromates, Synta66 and GSK-7975A ( Figure I in the online-only Data Supplement) 23 ; and furthermore the diphenylborate 2APB, initially used as InsP 3 receptor inhibitor at high concentrations but now recognized as a more potent antagonist of Ca 2+ entry. 24, 25 Other tested compounds were LOE-908Cl and the nitrophenyl pyridine, MRS1845, both of which block Ca 2+ entry in HL-60 cells. 26, 27 Because platelets lack voltage-dependent Ca 2+ channels, 3 specific inhibitors of these were not tested. At maximally effective concentrations, Synta66 and 2APB (10 μmol/L) as well as SKF96365 and GSK-7975A (100 μmol/L) nearly completely blocked the Ca 2+ entry signal evoked by CaCl 2 addition, whereas they moderately reduced Ca 2+ mobilization from stores with 10% to 30% ( Figure 1A and 1B) . In contrast, MRS1845 up to 100 μmol/L did not suppress the Ca 2+ entry. The compound LOE-908Cl strongly interfered with the fura-2 fluorescence signal and, hence, was not used for experiments. Dose-response curves for all inhibitors showed that the IC 50 concentration for SOCE in washed platelets increased in the order of Synta66<2APB<GSK-7975A<SKF96365<MRS1845 ( Figure 1C ).
Platelet procoagulant activity resulting from surface exposure of PS is known to be greatly impaired by deficiency or mutations of the SOCE channel, Orai1. 6, 10 Using fluorescentlabeled annexin A5, we investigated the ability of all inhibitors to affect PS exposure in platelets stimulated with convulxin and thrombin. Flow cytometric analysis showed that Synta66 (10 μmol/L), 2APB (10 μmol/L), GSK-7975A (30 μmol/L), and SKF96365 (100 μmol/L) each potently suppressed the fractions of PS-exposing platelets ( Figure II in the online-only Data Supplement). Quantitative analysis indicated that among these, at a maximally effective concentration, 2APB was the most potent inhibitor. These results thus show that all tested SOCE inhibitors restrain platelet procoagulant activity.
SOCE Blockers Suppress Human Platelet Activation in Plasma and Whole-Blood Thrombus Formation
In plasma or whole blood systems, lipophilic inhibitors often need to be added at 10× to 50× higher concentrations than in nonplasma-based buffer systems to affect platelet function. 28 This also appeared to be the case for the SOCE inhibitors. When added to platelet-rich plasma, concentrations of 100 μmol/L Synta66, 2APB, or GSK-7975A were required for inhibition of convulxin-induced Ca 2+ rises and PS exposure with 41% to 49% (data not shown). To verify that these inhibitors influenced platelet procoagulant activity, the effects of Synta66, 2APB, or GSK-7975A (100 μmol/L) in platelet-rich plasma were measured on thrombin generation. Upon triggering with 1 pmol/L tissue factor, peak heights of thrombin generation were reduced with Synta66, 2APB, and GSK-7975A to 29±2%, 58±2%, and 28±2% of control, respectively. SKF96365 (100 μmol/L) was inactive in platelet-rich plasma (not shown).
Because Synta66, 2APB, or GSK-7975A retained their inhibitory activity in plasma, the compounds were tested in whole-blood thrombus formation. Therefore, phenylanalyl-prolyl-arginine chroromethyl ketone-anticoagulated human blood was flowed at high shear rate over collagen (ie, a condition where the thrombusforming process is regulated via Orai1-mediated platelet activation). 5 In this flow perfusion assay, collagen-adhered platelets are activated in a GPVI-dependent way by elevating intracellular Ca 2+ and aggregating and exposing PS. 15, 17 With all 3 inhibitors, the deposition of platelets on the collagen surface was markedly reduced in comparison with the vehicle control, as was the number of platelets exposing PS (Figure 2A and 2B) . Subsequent experiments with fluo-4-loaded platelets indicated that, at the same flow conditions, all 3 SOCE inhibitors did reduce the Ca 2+ rises of collagen-adhered platelets by 25% ( Figure 3) .
In control flow experiments, the effect of chelation of extracellular Ca 2+ by EGTA was examined. This resulted in the formation of small aggregates on the collagen surface, while PS exposure (measured with fluorescein isothiocyanate-labeled lactadherin) was also reduced by >90%. With EGTA present, the extra addition of 2APB, Synta66, or GSK-7975A (100 μmol/L) was without further effect on PS exposure and platelet deposition (surface area coverage: vehicle 7.8%; 2APB 7.8%; Synta66 8.3%; GSK-7975A 7.5%). Together, these data demonstrate that the tested compounds reduce Ca 2+ signaling and markedly suppress collagen-dependent thrombus formation of flowing human blood.
SOCE Blockers Suppress Murine Platelet Responses and Thrombus Formation
Considering that Orai1 forms the main SOCE channel in mouse platelets, 2,5,10 we used platelets from wild-type and Orai1-deficient mice to verify the selectivity of the inhibitory compounds for this Ca 2+ channel. In fura-2-loaded platelets from wild-type mice, the GPVI agonist CRP caused a prominent Ca 2+ rise in the presence of CaCl 2 attributable to SOCE ( Figure III in the online-only Data Supplement). This Ca 2+ rise with CRP was inhibited by >50% with Synta66 (10 μmol/L), 2APB (100 μmol/L), or GSK-7975A (100 μmol/L). In fura-2-loaded Orai1 −/− platelets, CRP evoked a much lower Ca 2+ response because of the absence of SOCE, which is in confirmation with earlier results. 5, 10 The Ca 2+ signal in knockout platelets was not affected by Synta66 or 2APB, whereas GSK-7975A was slightly inhibitory ( Figure III in the online-only Data Supplement). In wild-type platelets, all 3 inhibitors markedly suppressed thrombin-evoked Ca 2+ rises, whereas Synta66 and GSK-7975A but not 2APB had a limited reducing effect on the already impaired thrombin-evoked Ca 2+ rise in Orai1 −/− platelets. Together, these data point to 2APB as a most specific inhibitor of murine Orai1.
We then examined the efficacy of the compounds to suppress murine thrombus formation in flow experiments over collagen with isolated wild-type blood. In comparison with the vehicle condition, all 3 compounds (100 μmol/L) significantly lowered platelet deposition by ≈30% (leaving small aggregates) and PS exposure by 50% ( Figure 4A and 4B) . This was again accompanied by a marked reduction in Ca 2+ responses of the collagen-adherent platelets ( Figure 4C ). The relatively high reduction in PS exposure in comparison with platelet aggregate formation is compatible with the results of flow studies using Orai1 −/− blood. 5, 10 Earlier data have indicated that platelet adhesion and aggregation are less dependent on the Ca 2+ signal than PS exposure, which requires a prolonged elevation in cytosolic Ca 2+ . 1 Flow experiments were also performed with Orai1 −/− blood to check for potential non-Orai effects of 2APB, Synta66, and GSK-7975A ( Figure IV in the online-only Data Supplement). However, in the absence of Orai1 none of these compounds (100 μmol/L) caused a further reduction in platelet deposition or PS exposure. Together, this points to Orai1 as principal target of these inhibitors in whole-blood thrombus formation.
Given the marked effects of 2APB in flow experiments, this compound was used to examine the consequences of SOCE inhibition on arterial thrombus formation in vivo. Wildtype mice were injected with a bolus of 2APB (3 mg/kg) or vehicle solution, and blood was taken after 60 minutes to assess collagen-dependent thrombus formation under flow. The in vivo 2APB treatment resulted in the formation of smaller platelet aggregates and in a marked decrease in platelet deposition by ≈35% ( Figure 5A and 5B) . This resembled the diminished thrombus formation after in vitro addition of 2APB (Figure 4) .
Because platelet activation via glycoprotein Ib, GPVI, and Orai1 significantly contributes to the development of brain infarction after thrombus formation in the cerebral arteries, 5, 20 we tested the efficacy of 2APB on this process using an established experimental stroke model. Herein, ischemic stroke is evoked by transient MCA occlusion, and the brain infarct volume is assessed after 1 day. Administration of 2APB to wild-type mice significantly reduced the infarction volume by ≈30% compared with the vehicle control ( Figure 5C ). In Figure 3 . Store-operated Ca 2+ entry (SOCE) blockers attenuate Ca 2+ signals during thrombus formation. Human phenylanalylprolyl-arginine chroromethyl ketone-anticoagulated blood was supplemented with 10% autologous fluo-4-loaded platelets and preincubated as described in Figure 2 . Blood was perfused 4 minutes over collagen at a shear rate of 1000/s, while fluorescence video images were recorded to determine rises in Ca 2+ . A, Representative Ca 2+ traces from single, adhered platelets, represented as pseudo-ratio F/F 0 . B, Averaged Ca 2+ traces from >40 platelets per condition. C, Quantification of mean Ca 2+ rises during 90 to 150 s after initial adhesion. Mean±SEM, *P<0.05, **P<0.01.
Orai1 −/− mice, transient MCA occlusion caused a smaller infarction volume, which is in agreement with previous results. 5 Importantly, administration of 2APB to Orai1 −/− mice did not result in a further decrease in infarction size ( Figure  5C and 5D ). Altogether, these results indicate that the blockage of platelet SOCE via Orai1 has a thromboprotective effect.
Discussion
In the present study, we show for the first time that pharmacological blockage of platelet SOCE channels has a thromboprotective potential by suppressing thrombus formation and reducing platelet procoagulant activity. In both human and mouse platelets, the novel compounds Synta66, GSK-7975A, and 2APB, at concentrations that inhibited SOCE, effectively antagonized whole-blood thrombus formation and PS exposure. These results are in agreement with the earlier reported impaired thrombus formation and platelet procoagulant activity in mice with Orai1-deficient platelets 5, 10 and in human platelets with a dysfunctional Orai1 R91W mutation. 6 In contrast, we found that the compound SKF96365, earlier identified as blocker of Ca 2+ influx in platelets, was ineffective in the presence of blood plasma.
We find that in suspensions of washed human platelets, 2APB, Synta66, and GSK-7975A effectively suppressed agonist-induced Ca 2+ influx via SOCE (>85%), at concentrations where Ca 2+ mobilization from stores was only moderately affected (10%-25%). The mechanism of this moderate reduction of Ca 2+ mobilization is unclear. Similar to 2ABP, both inhibitors may modulate InsP 3 receptor function (eg, by affecting Ca 2+ -induced Ca 2+ release). Alternatively, they may interfere in a proposed interaction of InsP 3 receptors with Orai1 channels. 29 Both 2APB and Synta66 abrogated GPVI-induced Ca 2+ signaling in wild-type but not in Orai1 −/− mouse platelets, whereas GSK-7975A caused limited additional inhibition in Orai1 −/− platelets. Furthermore, 2APB did not affect thrombininduced Ca 2+ signaling in Orai1 −/− mouse platelets, thus pointing to this compound as a more selective inhibitor of the Orai1 channels. Synta66 has been shown to block I CRAC currents in mast cells, 23 whereas the structural analog GSK-7975A has not been tested before. The compound 2APB was previously considered to be an antagonist of InsP 3 receptors but later identified as a much more potent Ca 2+ influx blocker, 24, 25, 30 which is confirmed by the current data. Other tested compounds were much less effective in inhibiting SOCE and could not be used in the presence of blood plasma (ie, MRS1845 and SKF96365, the first described antagonist of Ca 2+ influx in isolated platelets and leukocytes). 22 In GPVI-stimulated platelets, Synta66, GSK-7975A, and 2APB markedly inhibited the procoagulant response (ie, PS exposure) at concentrations that also affected Ca 2+ responses. This inhibition was observed in washed platelets with thrombin as coagonist and in collagen-adhered platelets after blood perfusion. Previous studies suggested a role of Ca 2+ influx in PS exposure of human platelets, 31, 32 and the present data are the first to demonstrate that pharmacological blockage of SOCE suppresses this process in whole blood. However, the moderate reduction in Ca 2+ responses in collagen-adhered platelets points to partial inhibition of SOCE in whole blood despite the presence of high concentrations (10 −4 mol/L) of blockers, which is compatible with their incomplete inhibition of PS exposure. Given the limited water solubility of all tested compounds, next generation Orai1 antagonists preferably combine reduced hydrophobicity with increased affinity to the Ca 2+ channel.
Injection of a single bolus of 2APB into wild-type mice effectively reduced whole-blood thrombus formation ex vivo in mouse and significantly diminished brain infarct volume after middle cerebral artery occlusion (ie, an arterial thrombosis model known to rely on platelet Orai1 activity). 5 Given the fact that this model of brain infarction relies on glycoprotein Ib-and GPVI-dependent platelet activation and on factor XII-dependent thrombin generation, 20, 33 the protective effect of 2APB can rely on the inhibition of both thrombus formation and platelet procoagulant activity.
In conclusion, we have shown that SOCE inhibitors including 2APB, directed against Orai1, have a high potential in reducing platelet-dependent coagulation and thrombus formation. The relatively high doses needed for the presently available SOCE (Orai1) inhibitors, however, urge for a search to higher affinity channel blockers before starting preclinical studies. Given the reported immune deficiency of patients with missense Orai1 mutations, 34 total or long-term blockage of SOCE may not be desirable in the treatment of patients with thrombosis. Hence, possible toxic side effects after administration of Orai1 channel blockers need to be monitored thoroughly. With such compounds available, our data indicate that the platelet Orai1 channel is a novel target for attacking arterial thrombosis to brain infarction.
